By Jonathan Weber
CVS Health (CVS) trades around five-year lows due to uncertainties about the company's future growth and worries about its rising debt. The company's acquisition of Aetna was strategically sound, however, and strong cash generation should allow CVS Health to reduce its leverage substantially over the next couple of years.
Still, the market remains pessimistic. CVS shares have declined ~16% year-to-date, compared with a 19% gain for the broader S&P 500 Index. As a result, we now view CVS as one of the most undervalued healthcare dividend stocks in the